- Datum05.06.2025
- Uhrzeit08:55 - 18:30 Uhr
- Veranstalter
stock3
stock3
Moderator
Lonza Group AG Aktie
Verkaufen
Kaufen
Lonza Group AG Chart
Lonza Group AG Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (SIX)
-1,06 %
Intraday
0,11 %
1 Woche
-4,36 %
1 Monat
4,74 %
Seit Jahresbeginn
16,31 %
1 Jahr
-2,03 %
3 Jahre
19,02 %
5 Jahre
325,15 %
10 Jahre
Passender Service zu Lonza Group AG
Webinar zu Lonza Group AG
Kursinformationen (SIX)
- Tagestief / Hoch (Fr)-
- 52W-Tief / Hoch (Fr)467,800-616,000
- Jahrestief / Hoch (Fr)467,800-616,000
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Lonza Group AG
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2028 (e) | ||
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 13.05.2025 | 2024 | 2,00 Fr | 0,35 % |
| 13.05.2024 | 2023 | 2,00 Fr | 0,38 % |
| 09.05.2023 | 2022 | 1,75 Fr | 0,30 % |
| 09.05.2022 | 2021 | 1,50 Fr | 0,27 % |
| 10.05.2021 | 2020 | 1,50 Fr | 0,26 % |
| 30.04.2020 | 2019 | 1,375 Fr | 0,32 % |
| 07.04.2010 | 2009 | 1,75 Fr | 2,03 % |
| 16.04.2009 | 2008 | 1,75 Fr | 1,66 % |
| 01.04.2008 | 2007 | 1,75 Fr | 1,33 % |
| 03.04.2007 | 2006 | 1,50 Fr | 1,31 % |
| 28.03.2006 | 2005 | 1,30 Fr | 1,47 % |
| 15.04.2005 | 2004 | 1,30 Fr | 1,71 % |
| 06.04.2004 | 2003 | 1,30 Fr | 1,98 % |
| 01.04.2003 | 2002 | 1,90 Fr | 2,48 % |
| 03.04.2002 | 2001 | 19,00 Fr | - |
| 04.04.2001 | 2000 | 15,00 Fr | - |
| 16.06.2000 | 1999 | 10,00 Fr | - |
Termine von Lonza Group AG
- Jul23Lonza Group AGQ2 2025 Earnings Release
- Jan28Lonza Group AGQ4 2025 Earnings Release
- Jul29Lonza Group AGQ2 2026 Earnings Release
Beschreibung
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
